ENSPRYNG

This brand name is authorized in United States. It is also authorized in Canada, Croatia, Ecuador, Estonia, Finland, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Nigeria, Poland, Romania, Turkey.

Active ingredients

The drug ENSPRYNG contains one active pharmaceutical ingredient (API):

1	Satralizumab UNII YB18NF020M - SATRALIZUMAB
	Satralizumab is a recombinant humanised immunoglobuline G2 (IgG2) monoclonal antibody (mAb) that binds to soluble and membrane-bound human IL-6 receptor (IL-6R) and thereby prevents IL-6 downstream signalling through these receptors.
	Read more about Satralizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ENSPRYNG Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)
ENSPRYNG Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AC19		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC19

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02499681
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	189-MBE-0421
EE	Ravimiamet	1856099
FI	Lääkealan turvallisuus- ja kehittämiskeskus	446332
HK	Department of Health Drug Office	66941
IL	מִשְׂרַד הַבְּרִיאוּת	8766
JP	医薬品医療機器総合機構	6399428G1024
LT	Valstybinė vaistų kontrolės tarnyba	1092899, 1093341
NG	Registered Drug Product Database	A6-100128
Switch country to Nigeria in order to find specific presentations of ENSPRYNG
PL	Rejestru Produktów Leczniczych	100454392
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67936001
TR	İlaç ve Tıbbi Cihaz Kurumu	8699505951027
US	FDA, National Drug Code	50242-007